Company Overview - Koryx Copper Inc. is a Canadian copper development company focused on the Haib Copper Project in Namibia and has a portfolio of copper exploration licenses in Zambia [2] - The Haib Copper Project is a large, advanced copper/molybdenum porphyry deposit with a long history of exploration and development by multiple operators [2] Project Details - The Haib project has a current mineral resource of 414 million tonnes (Mt) at 0.35% copper (Cu) for 1,459 million tonnes of contained copper in the Indicated category, and 345 Mt at 0.33% Cu for 1,136 million tonnes of contained copper in the Inferred category [3] - The mineralization at Haib is typical of a porphyry copper deposit, characterized by dominant chalcopyrite with minor bornite and chalcocite [4] Future Prospects - Additional studies are being conducted to demonstrate Haib as a future long-life, low-cost, low-risk open pit, sulphide flotation copper project, with potential for additional copper production from heap leaching [3] - Further details regarding the Haib Copper Project can be found in the "NI 43-101 Technical Report – August 2024 Mineral Resource Estimate for the Haib Copper Project, Namibia" [5]

Core Viewpoint - A class action has been filed against UroGen Pharma Ltd. due to allegations of improper trial conduct for its lead drug candidate, UGN-102, which is intended to treat low-grade intermediate risk non-muscle invasive bladder cancer [1][2]. Summary by Sections Allegations - Robbins LLP is investigating allegations that UroGen Pharma Ltd. failed to conduct a proper trial for UGN-102, with the rolling new drug application (NDA) submitted on August 14, 2024 [2]. FDA Concerns - On May 16, 2025, the FDA expressed doubts regarding the efficacy data submitted for UGN-102, highlighting that the ENVISION study lacked a concurrent control arm, making the primary endpoints difficult to interpret [3]. - The FDA had previously recommended a randomized trial design multiple times during the product's development, which UroGen did not follow [3]. Stock Price Impact - Following the FDA's concerns, UroGen's stock price dropped by $2.54, or 25.8%, closing at $7.31 per share on May 16, 2025 [3]. - On May 21, 2025, the Oncologic Drugs Advisory Committee voted against the approval of UGN-102, leading to a further decline in stock price by $3.37, or 44.7%, closing at $4.17 per share [4]. Class Action Details - The complaint alleges that UroGen did not disclose critical information regarding the study design and its implications for the NDA approval process, including the lack of a concurrent control arm and the challenges in demonstrating the drug's effectiveness [5]. - Shareholders may be eligible to participate in the class action, with options to serve as lead plaintiff or remain absent class members [6]. Company Background - Robbins LLP has been recognized for its efforts in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance since 2002 [7].

Core Insights - Tesla's humanoid robot Optimus is considered pivotal to the company's future by CEO Elon Musk [1][2] - The expected cost of the Optimus robot is projected to be less than that of a car [1] - The departure of a key artificial intelligence executive, Milan Kovac, represents a setback for the Optimus project [1][2] Company Developments - Milan Kovac, who was a vice president of engineering, played a significant role in the development of the Optimus robot [2] - The Optimus project aligns with Musk's vision of evolving Tesla from an electric vehicle manufacturer to a robotics and artificial intelligence company [2]

Core Viewpoint - Halper Sadeh LLC is investigating the fairness of the proposed sale of Provident Bancorp, Inc. to NB Bancorp, Inc. for Provident shareholders [1][3] Group 1: Transaction Details - Provident shareholders will receive either 0.691 shares of NB Bancorp common stock or $13.00 in cash for each share of Provident common stock [1] - The investigation focuses on whether the board of directors of Provident acted in the best interest of shareholders during the transaction [3] Group 2: Legal Considerations - The investigation questions if Provident and its board violated federal securities laws or breached fiduciary duties by not obtaining the best possible consideration for shareholders [3] - Halper Sadeh LLC may seek increased consideration, additional disclosures, and other benefits for Provident shareholders [4]

10% Annual Rate Level Distribution Policy Conditional Tender Offer for 10% of Outstanding SharesNEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Japan Smaller Capitalization Fund, Inc. (the “Fund”) (NYSE: JOF) today announced that its Board of Directors (the “Board”) has approved two initiatives aimed at addressing the Fund’s trading discount. These initiatives include a level distribution plan and a conditional tender offer. The Board believes these actions reflect the Fund’s ongoing commitment to enhancing sha ...

NEWTOWN, Pa., June 06, 2025 (GLOBE NEWSWIRE) -- Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving Humana Inc. (“Humana”) (NYSE: HUM), resulting from allegations of providing potentially misleading business information to the investing public. If you have non-public information that could assist in the Humana investigation, or if you are a Humana investor who suffered a loss and would like to learn more, you can provide your information HERE. You can also con ...

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who acquired Reckitt Benckiser Group PLC American Depository Shares (ADSs) between January 13, 2021, and July 28, 2024, alleging that the company misled investors regarding the safety of its Enfamil baby formula [1][2]. Allegations - The lawsuit claims that Reckitt failed to inform investors and consumers about the increased risk of necrotizing enterocolitis (NEC) in preterm infants consuming its cow's milk-based formula, Enfamil, and the potential negative impact on sales and legal exposure [2]. - A jury in Illinois awarded $60 million in a case against Mead Johnson, finding negligence in failing to warn about the risks associated with cow's milk-based formula, which led to a significant drop in Reckitt's ADS price [3]. - Following a similar case in Missouri, where Abbott Laboratories was found liable for NEC-related damages, Reckitt's ADS price also experienced a notable decline [4]. Class Action Participation - Shareholders interested in serving as lead plaintiffs in the class action must file a motion by August 4, 2025, but participation is not required to be eligible for recovery [5].

Core Viewpoint - Integral Metals Corp. has successfully closed a non-brokered private placement offering of common shares, raising gross proceeds of US$400,000 at a price of US$0.70 per share [1][2]. Group 1: Private Placement Details - The private placement consists of common shares priced at US$0.70 each, resulting in total gross proceeds of US$400,000 [1]. - The net proceeds from the private placement will be allocated for expenditures on mineral exploration properties and general working capital [2]. - All securities issued under the private placement are subject to a hold period of four months and one day [2]. Group 2: Company Overview - Integral Metals Corp. is engaged in mineral exploration for critical minerals, including gallium, germanium, and rare earth elements, aiming to contribute to the development of a domestic supply chain for these minerals [4]. - The company holds properties in mining-friendly jurisdictions in Canada and the USA, including the Northwest Territories, Manitoba, and Montana, where it has received regulatory support for its exploration efforts [4].

Lululemon lovers are already stretching their wallets to the limit — and now they’ve had enough.Fans and critics alike were clucking their tongues Friday after the athleisure giant warned customers they’d soon be paying even more for already-pricey workout gear — following a whopping stock nosedive.The culprit? President Donald Trump’s tariffs — and, apparently, broke Americans tightening their purse strings.“We experienced lower store traffic in the Americas, partially reflective of economic uncertainty, i ...

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, June 06, 2025 (GLOBE NEWSWIRE) -- Pan American Energy Corp. (CSE: PNRG | FRA: SS60) (“Pan American” or the “Company”) announces, further to its news release of May 29, 2024, that it has issued, 205,841 common shares in the capital of the Company (the “Settlement Shares”), at a deemed value of $0.20 per Settlement Share, in full and final settlement of accrued and outstanding debt to certain c ...